Log in

Apricus Biosciences Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
+0.13 (+14.44 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $1.03
50-Day Range N/A
52-Week Range
Now: $1.03
Volume2.89 million shs
Average Volume558,386 shs
Market Capitalization$29.02 million
P/E RatioN/A
Dividend YieldN/A
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. Its portfolio includes late-stage clinical assets targeting psychiatric and movement disorders. The company is headquartered in New York, NY.
Read More
Apricus Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:APRI
Phone(646) 293-2100



Sales & Book Value

Annual Sales$5.76 million
Book Value$0.29 per share


Net Income$320,000.00


Market Cap$29.02 million
Next Earnings DateN/A
OptionableNot Optionable

Receive APRI News and Ratings via Email

Sign-up to receive the latest news and ratings for APRI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Apricus Biosciences (NASDAQ:APRI) Frequently Asked Questions

What stocks does MarketBeat like better than Apricus Biosciences?

Wall Street analysts have given Apricus Biosciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Apricus Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Apricus Biosciences' earnings last quarter?

Apricus Biosciences, Inc. (NASDAQ:APRI) released its quarterly earnings results on Wednesday, October, 31st. The company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.02.
View Apricus Biosciences' earnings history

Who are some of Apricus Biosciences' key competitors?

What other stocks do shareholders of Apricus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apricus Biosciences investors own include The Scotts Miracle-Gro (SMG), Pfizer (PFE), Grubhub (GRUB), The Boston Beer (SAM), Palatin Technologies (PTN), Synergy Pharmaceuticals (SGYP), Amicus Therapeutics (FOLD), Avon Products (AVP), Chesapeake Energy (CHKAQ) and Novavax (NVAX).

Who are Apricus Biosciences' key executives?

Apricus Biosciences' management team includes the following people:
  • Raj Mehra, Chairman, President, CEO & CFO
  • Warren W. Wasiewski, Chief Medical Officer
  • Jessica Kardish, Head-Clinical Operations
  • Tim Whitaker, Head-Research & Development
  • Anthony Marciano, Head-Corporate Communications

What is Apricus Biosciences' stock symbol?

Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI."

What is Apricus Biosciences' stock price today?

One share of APRI stock can currently be purchased for approximately $1.03.

How big of a company is Apricus Biosciences?

Apricus Biosciences has a market capitalization of $29.02 million and generates $5.76 million in revenue each year. The company earns $320,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis.

What is Apricus Biosciences' official website?

The official website for Apricus Biosciences is www.apricusbio.com.

How can I contact Apricus Biosciences?

Apricus Biosciences' mailing address is 11975 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at (646) 293-2100 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.